EP300 and prostate cancer: Notably, compared with previously reported p300/CBP degraders dCBP-1 (ref. 41) and JQAD1 (ref. 42), CBPD-409 exhibited enhanced degradation effects in prostate cancer cell lines (Extended Data Fig. 3p).